Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7583915 | 0.92 | CRHR1 (0.33) | BCL2OPRM1OPRD1OPRK1CRHR1 | |
| SCHEMBL7589128 | 0.90 | BCL2 (0.32) | BCL2OPRM1OPRD1OPRK1CRHR1 | |
| SCHEMBL7866024 | 0.89 | OPRM1 (0.35) | BCL2OPRM1OPRD1OPRK1CRHR1 | |
| SCHEMBL7582965 | 0.81 | OPRM1 (0.35) | BCL2OPRM1OPRD1OPRK1CRHR1 | |
| SCHEMBL7589160 | 0.79 | OPRM1 (0.36) | BCL2OPRM1OPRD1OPRK1 | |
| SCHEMBL7598555 | 0.78 | CFB (0.41) | CRHR1 | |
| SCHEMBL7658816 | 0.76 | HTT (0.44) | — | |
| SCHEMBL8330304 | 0.72 | BCL2 (0.36) | BCL2OPRM1OPRD1OPRK1CRHR1 | |
| SCHEMBL8329405 | 0.72 | BCL2 (0.36) | BCL2OPRM1OPRD1OPRK1CRHR1 | |
| SCHEMBL6369819 | 0.70 | BCL2 (0.38) | BCL2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0941223-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-15 | — | — | EP | claimed |
| WO-1998021200-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-05-22 | — | — | WO | claimed |
| US-6469041-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | NEUROGEN CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6300360-B1 | FOR THERAPY OF STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6127399-A | TREATING POST TRAUMATIC STRESS DISORDER AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5973152-A | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION | 1999-10-26 | — | — | US | disclosed |
| EP-0941223-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998021200-A1 | CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | CRH, CRHR1, CRHR2 | BCL2 4733/4885OPRM1 65/4885OPRD1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.